#Flash: Intravitreal Aflibercept is Efficacious in treatment
This Study aimed to evaluate the vascular endothelial growth factor blockade therapy with intravitreal aflibercept injections in eyes with severe nonproliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). 402 adults with Diabetic Retinopathy Severity Scale (DRSS) level 47 or 53 were included. Results showed that at 24 weeks, treatment with aflibercept resulted in a greater improvement in DRSS level in 157 eyes in the combined aflibercept groups than in the control group. At 52 weeks, 88 eyes in the aflibercept 2q16 group and 107 eyes in the aflibercept 2q8/PRN group showed a greater improvement in DRSS level. Finally, at 24, 52, and 100 weeks, significantly more eyes with moderately severe to severe NPDR treated with aflibercept demonstrated a 2-step or greater improvement in DRSS level.

If you find this post insightful, please like, comment and share.

Source: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2782556